GlobeNewswire

Ascentage Pharma to Participate in Two Upcoming Investor Conferences in London
03/11/2026
ROCKVILLE, Md., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage Pharma” or the “Company”), a global, commercial-stage, integrated biopharmaceutical company [...]
ARCHIMED Life Science Tools & Services Completes Acquisition of Standard BioTools’ Microfluidics Business, Now Biomark Scientific
03/11/2026
Business will operate as Biomark Scientific, a leader in accessible, scalable and automated genomic workflows powered by proprietary microfluidics technology BOSTON, Mass., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Global [...]
Helus Pharma to Participate in the Guggenheim Healthcare Innovation Conference
03/11/2026
CEO Michael Halstead to participate in a fireside chat on November 9, 2026 at 3:00 p.m. EDT NEW YORK and TORONTO, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Helus Pharma Inc. (Nasdaq: HELP) (Cboe CA: HELP) (the “Company” or “ [...]
BridgeBio to Present New Acoramidis Data on Heart Failure Events in ATTR-CM at the American Heart Association Scientific Sessions 2026
03/11/2026
PALO ALTO, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) ("BridgeBio" or the "Company"), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for [...]
Coloplast A/S - Annual Report 2025/26 & Remuneration Report 2025/26
03/11/2026
FY 2025/26 organic growth was 6% and EBIT growth 1 in constant currencies was 4%. Reported revenue in DKK grew 4%, reflecting 2%-points negative impact from currencies. Organic growth rates by business area: Ostomy Care [...]
L'équipe de l'étude GLORIA reçoit le Prix allemand de la médecine universitaire 2026 pour ses travaux de recherche sur le glioblastome avec l'inhibiteur de CXCL12 NOX-A12
03/11/2026
L'équipe de l'étude GLORIA reçoit le Prix allemand de la médecine universitaire 2026 pour ses travaux de recherche sur le glioblastome avec l'inhibiteur de CXCL12 NOX-A12 Des chercheurs issus de six centres médicaux [...]
GLORIA Study Team Receives the 2026 German University Medicine Prize for Its Glioblastoma Research with CXCL12 Inhibitor NOX-A12
03/11/2026
GLORIA Study Team Receives the 2026 German University Medicine Prize for Its Glioblastoma Research with CXCL12 Inhibitor NOX-A12 Researchers from six German university medical centers have received the 2026 German [...]
Global Pharmaceutical Company Commits to a Dual-Site Deal with AGC Biologics Exceeding €0.5 Billion
03/11/2026
Agreement builds on customer’s long-term deal in new Yokohama facility for five commercial biologics programs, now allocating an additional six commercial programs to Copenhagen facility to consolidate high-volume, [...]
Transactions in connection with share buy-back program
03/11/2026
Company announcement no. 44 - 26 03 November 2026 Transactions in connection with share buy-back program On 4 March 2026 NTG Nordic Transport Group (“NTG”) announced a share buy-back program, as described in company [...]
Upgrade of revenue and operating profit guidance
03/11/2026
ANNOUNCEMENT NO. 324 3 November 2026 ChemoMetec maintained its positive momentum in the months of the 2026/27 financial year, supported by higher-than-expected demand for our instruments, with the NC-203 being a key [...]
Human Appeal Receives Canadian Parliamentary Delegation to Rare Hospital in Northwest Syria
03/11/2026
MISSISSAUGA, Ontario, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Human Appeal Canada welcomed a Canadian Parliamentary and Humanitarian Delegation to Syria, which included a visit to Al-Iman Hospital in Sarmada , where a baby [...]
Philips delivers strong order intake growth, comparable sales growth and strong margin expansion in Q3; 2026 outlook reiterated
03/11/2026
November 3, 2026 Q3 2026 Group performance Comparable order intake increased by 8%, driven by strong Diagnosis & Treatment Group sales of EUR 4.4 billion, reflecting 3% comparable sales growth Income from operations [...]
argenx to Present at Upcoming Investor Conferences
03/11/2026
November 3, 2026 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), the immunology innovation company, today announced that members of the management team will participate in the following investor [...]
Invitation to Idorsia's webcast and conference call to provide more context on the opportunity and launch approach for TRYVIO/JERAYGO
03/11/2026
Idorsia will host an investor webcast and conference call to provide more context on the opportunity and launch approach for TRYVIO™/JERAYGO™ (aprocitentan). Date: Wednesday, November 4, 2026 Time: 14:00 CET / 13:00 GMT [...]
Strong Cresemba® (isavuconazole) sales in Europe trigger USD 37.5 million milestone payment to Basilea
03/11/2026
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, November 03, 2026 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of [...]
New research initiative will utilise AI to optimise Nordic energy grid capacity, improve resilience and prepare for future needs
03/11/2026
A new Nordic research initiative will develop artificial intelligence-based solutions to help power grid operators optimise the use of existing grid infrastructure, handle growing uncertainty and keep power grids [...]
ONWARD Medical Delivers Revenue of EUR 2.5M in Q3 2026, with Sustained Commercial Momentum and Strong Clinical Execution
03/11/2026
EINDHOVEN, the Netherlands, Nov. 03, 2026 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD – US ADR: ONWRY), the leading neurotechnology company pioneering therapies to restore movement, function, and [...]
Rhythm Pharmaceuticals and LG Chem Enter into Amendment to Bivamelagon Exclusive License Agreement
03/11/2026
-- Amendment revised royalty structure from low-to-mid-single digits to 1% on global net sales of Rhythm MC4R agonists, including setmelanotide, bivamelagon and RM-718 -- -- Rhythm to pay LG Chem additional fixed [...]
Opus Genetics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
02/11/2026
RESEARCH TRIANGLE PARK, N.C., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients [...]

Pages

Other news

Test 2

Lorem ipsum

Test 1

Lorem upsum